Novo Nordisk (NVO) faced a setback with an earnings miss, causing a 4% drop in its stock price. This decline added to the challenges the company has been facing, including a recent management shake-up and lower guidance despite strong sales of its GLP-1 drugs Ozempic and Wegovy. The stock has plummeted over 46% year to date.
CFO Karsten Munk Knudsen expressed surprise at the sudden leadership change earlier in the year, with CEO Lars Jørgensen being ousted and Mike Doustdar taking his place. Knudsen acknowledged that in a competitive industry, such changes are not uncommon, but it was unexpected in the context of Novo Nordisk.
The US market has been particularly challenging for Novo Nordisk, as it lost its lead to competitor Eli Lilly despite having a first-mover advantage. The compounding market, where copycats are allowed under special circumstances, has posed a significant threat to Novo Nordisk’s market share. Knudsen revealed that about one-third of current GLP-1 prescriptions in the US are from the compounding market.
In addition to competition and copycats, Novo Nordisk has been under pressure from the Trump administration to lower drug prices for consumers. The company was one of 17 companies to receive a letter demanding reduced costs for current and new products. Outgoing CEO Lars Jørgensen highlighted that the company’s Medicaid prices are already lower than in Europe.
Despite doubts raised by experts about the success of cash markets, Knudsen remains optimistic about the potential. He mentioned that 10% of Wegovy patients in the US are paying cash through NovoCare, and he believes the cash channel will continue to grow in the future. The compounding market provides a glimpse into this potential, with one-third of Wegovy customers being cash-paying.
Novo Nordisk recently cut ties with Hims and Hers over its refusal to stop selling compounded semaglutide. Hims and Hers offer copycat drugs at lower prices than NovoCare, indicating the challenges Novo Nordisk faces in the market.
Anjalee Khemlani, the senior health reporter at Yahoo Finance, covers a wide range of healthcare topics, including GLP-1s. Follow her on social media platforms for the latest updates.
For more financial and business news, visit Yahoo Finance for the latest earnings reports and analysis. Stay informed about company earnings news and expectations to make well-informed decisions.
